Lucia Simoni, Filippo Recenti, Barbara Roncari, Laura Tanzini, Vincenzo Bagnardi, Giovanni Fiori, Alessandra Ori
{"title":"The authorization process of observational studies in Italy: exploring two decades of Ethics Committee approval data.","authors":"Lucia Simoni, Filippo Recenti, Barbara Roncari, Laura Tanzini, Vincenzo Bagnardi, Giovanni Fiori, Alessandra Ori","doi":"10.4415/ANN_25_02_03","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The recent guideline from the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) on observational studies prompts a broader reflection on the impact of regulations on clinical research and real-world evidence. While regulations are necessary to ensure ethical and scientific standards, their effectiveness in improving research quality is unclear. It is also uncertain whether these regulations strengthen clinical research or create bureaucratic obstacles. This quantitative, \"before and after\" study investigates the impact of the 2008 AIFA guideline and the 2018 General Data Protection Regulation (GDPR) on the complexity of ethical evaluation processes. As a secondary outcome, we also aimed to investigate whether the duration and probability of suspensions were influenced by intrinsic study characteristics (study design, rare disease, genetic data, post-authorization safety study).</p><p><strong>Materials: </strong>The study analyzed the ethical evaluation process of 112 observational multicenter studies with 2,875 submissions from 2002 to 2022, included in the database of Medineos srl. The number of suspensions observed in each evaluation process was a surrogate endpoint of complexity of evaluation process.</p><p><strong>Methods: </strong>Descriptive analyses and survival analysis were used to evaluate the total evaluation time, and a logistic model was applied to assess the probability of receiving a suspension.</p><p><strong>Results: </strong>The median (and interquartile range) evaluation time for \"pre-AIFA\" submissions was 70 (41-133) days, whereas it was 75 (45-122) days for \"post-AIFA\" submissions. The median evaluation time was 68 (41-113) days without suspension and 127 (84-180) days with suspension. Post-AIFA submissions had a higher likelihood of suspension. The median evaluation time for \"pre-GDPR\" submissions was 70 (42-123) days, whereas it was 90 (63-140) days for \"post-GDPR\" submissions. AIFA guidelines slightly increased evaluation time and the likelihood of suspension, suggesting improved quality control. GDPR increased evaluation time due to privacy evaluations but did not affect suspension probability. Intrinsic study factors did not impact evaluation duration or suspension probability.</p><p><strong>Conclusions: </strong>Although more extensive analyses are necessary, this study suggests that past changes in Italian regulations have affected the evaluation by the Ethics Committee (EC) and have also impacted the conduct of the observational studies. The data generated can be useful for monitoring the future impact of the recently published new AIFA guideline.</p>","PeriodicalId":502090,"journal":{"name":"Annali dell'Istituto superiore di sanita","volume":"61 2","pages":"109-115"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annali dell'Istituto superiore di sanita","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4415/ANN_25_02_03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The recent guideline from the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) on observational studies prompts a broader reflection on the impact of regulations on clinical research and real-world evidence. While regulations are necessary to ensure ethical and scientific standards, their effectiveness in improving research quality is unclear. It is also uncertain whether these regulations strengthen clinical research or create bureaucratic obstacles. This quantitative, "before and after" study investigates the impact of the 2008 AIFA guideline and the 2018 General Data Protection Regulation (GDPR) on the complexity of ethical evaluation processes. As a secondary outcome, we also aimed to investigate whether the duration and probability of suspensions were influenced by intrinsic study characteristics (study design, rare disease, genetic data, post-authorization safety study).
Materials: The study analyzed the ethical evaluation process of 112 observational multicenter studies with 2,875 submissions from 2002 to 2022, included in the database of Medineos srl. The number of suspensions observed in each evaluation process was a surrogate endpoint of complexity of evaluation process.
Methods: Descriptive analyses and survival analysis were used to evaluate the total evaluation time, and a logistic model was applied to assess the probability of receiving a suspension.
Results: The median (and interquartile range) evaluation time for "pre-AIFA" submissions was 70 (41-133) days, whereas it was 75 (45-122) days for "post-AIFA" submissions. The median evaluation time was 68 (41-113) days without suspension and 127 (84-180) days with suspension. Post-AIFA submissions had a higher likelihood of suspension. The median evaluation time for "pre-GDPR" submissions was 70 (42-123) days, whereas it was 90 (63-140) days for "post-GDPR" submissions. AIFA guidelines slightly increased evaluation time and the likelihood of suspension, suggesting improved quality control. GDPR increased evaluation time due to privacy evaluations but did not affect suspension probability. Intrinsic study factors did not impact evaluation duration or suspension probability.
Conclusions: Although more extensive analyses are necessary, this study suggests that past changes in Italian regulations have affected the evaluation by the Ethics Committee (EC) and have also impacted the conduct of the observational studies. The data generated can be useful for monitoring the future impact of the recently published new AIFA guideline.
导言:最近意大利药品管理局(Agenzia Italiana del Farmaco, AIFA)关于观察性研究的指南促使人们更广泛地反思法规对临床研究和现实世界证据的影响。虽然法规对于确保伦理和科学标准是必要的,但它们在提高研究质量方面的有效性尚不清楚。同样不确定的是,这些规定是加强了临床研究,还是制造了官僚主义障碍。这项定量的“前后”研究调查了2008年AIFA指南和2018年通用数据保护条例(GDPR)对道德评估过程复杂性的影响。作为次要结局,我们还旨在调查暂停的持续时间和概率是否受到研究固有特征(研究设计、罕见疾病、遗传数据、授权后安全性研究)的影响。材料:本研究分析了2002 - 2022年间112项观察性多中心研究的伦理评价过程,共纳入Medineos srl数据库的2875份文献。在每个评价过程中观察到的悬浮数是评价过程复杂性的替代终点。方法:采用描述性分析和生存分析评价总评价时间,采用logistic模型评价停学概率。结果:“pre-AIFA”提交的中位(和四分位数范围)评估时间为70(41-133)天,而“post-AIFA”提交的评估时间为75(45-122)天。中位评价时间为无停职68(41-113)天,停职127(84-180)天。提交aifa后,被暂停的可能性更高。“pre-GDPR”提交的中位评估时间为70(42-123)天,而“post-GDPR”提交的中位评估时间为90(63-140)天。AIFA指南略微增加了评估时间和暂停的可能性,表明质量控制得到了改善。由于隐私评估,GDPR增加了评估时间,但不影响暂停概率。内在研究因素不影响评估持续时间或暂停概率。结论:虽然需要更广泛的分析,但本研究表明,意大利法规过去的变化影响了伦理委员会(EC)的评估,也影响了观察性研究的进行。所产生的数据可用于监测最近发布的新的AIFA指南的未来影响。